Oruka advances ORKA-001/002 with 2026-27 catalysts and ample cash runway
Aug 10, 2026, 7:10 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Multiple near- and mid-term catalysts (Phase 3 start, 1Q27 readouts, additional indications via license amendment) plus a strengthened balance sheet reduce execution risk and could drive a rerating if readouts validate durability and dosing advantages observed in earlier data. Prior biotech catalysts have caused outsized moves when key readouts align with company guidance.
AI summary
What happened, with direct paths to the underlying reporting
Oruka reported Q2 2026 results and pipeline updates for ORKA-001/002. Major catalysts include EVERLAST-A data through Week 28 and 52-week data by December 2026, plus ORKA-001 Phase 3 initiation in 1H2027 and ORCA readouts in early 2027, supported by a $1.1B cash runway and a $700M equity upsizing.
EVERLAST-A Week 28 data due end of Q3 2026; 52-week data December 2026.
Phase 3 for ORKA-001 expected 1H2027; EVERLAST-B Week 16 data Q4 2026.
ORCA-SURGE Week 16 data moved to 1Q2027; ORCA-SPLASH initiated in HS.
ORKA-004 TL1A mAb enters clinic 4Q2026; Paragon IL-23 license amended for IBD.
Cash runway $1.1B; upsized $700M offering funds through ORKA-001 BLA.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Oruka Therapeutics reported strong efficacy for its ORKA-001 treatment, achieving 63.5% complete skin clearance among participants, with favorable safety data. The stock surged 39…
